A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer

Journal of Thoracic Oncology

Volumn 1, Issue 6, 2006, Pages 551-555

  Inoue, Akira ^a   Yamazaki, Koichi ^c   Maemondo, Makoto ^a   Suzuki, Takuji ^a   Kimura, Yuichiro ^a   Kanbe, Mariko ^d   Isobe, Hiroshi ^e   Nishimura, Masaharu ^c   Saijo, Yasuo ^b   Nukiwa, Toshihiro ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d Senseki Hospital   (Japan)

^e HOKKAIDO CANCER CENTER   (Japan)

Author keywords

Amrubicin; Carboplatin; Chemotherapy; Elderly; Phase I study; Small cell lung cancer

Indexed keywords

AMRUBICIN; CARBOPLATIN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT;

AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INFECTION; LIVER DYSFUNCTION; LUNG SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; AGE; CANCER STAGING; DRUG ADMINISTRATION; JAPAN; LUNG TUMOR; MORTALITY; PATHOLOGY; PATIENT SELECTION; PROGNOSIS; RISK FACTOR; SMALL CELL CARCINOMA; SURVIVAL; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34247853450     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200607000-00009     Document Type: Article

References (13)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606.
2. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
3. Murren J, Glatstein E, Pass HI. Small cell lung cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA (Eds.), Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia: Lippincott Williams and Wilkins, 2001. Pp. 983-1018.
4. Stephens RJ, Johnson DH. Treatment and outcomes for elderly patients with small cell lung cancer. Drugs Aging 2000;17:229-247.
5. Shepherd FA, Bezjak A. Treatment of small cell lung cancer in the elderly patients. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD, (Eds.). Lung Cancer: Principles and Practice, 2nd Ed. Philadelphia: Lippincott Williams and Wilkins, 2000. Pp. 1081-1091.
6. Sekine I, Fukuda H, Kunitoh H, Saijo N. Cancer chemotherapy in the elderly. Jpn J Clin Oncol 1998;28:463-473.
7. Yana T, Negoro S, Yokota M, Fukkuoka M. Phase II study of amrubicin (SM-5887), a 9-amino-anthracycline, in previously untreated patients with extensive stage small-cell lung cancer: a West Japan Lung Cancer Group Trial (abstract). Proc Am Soc Clin Oncol 1998;17:450a.
8. Ohe Y, Negoro S, Matsui K, et al. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol 2006;16:430-436.
9. Okamoto H, Watanabe K, Nishiwaki Y, et al. Phase II study of area under the plasma-concentration-versus-time curve based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol 1999;17:3540-3545.
10. Sekine I, Yamamoto N, Kunitoh H, et al. Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials. Cancer Treat Rev 2004 30:359-368.
11. Jara C, Gomez-Aldaravi JL, Tirado R, et al. Small-cell lung cancer in the elderly: is age of patient a relevant factor? Acta Oncol 1999;38:781-786.
12. Langer C, Manola P, Bernardo P, et al. Advanced age alone does not compromise outcome in fit non-small cell lung cancer (NSCLC) patients (Pts) receiving platinum (DDP)-based therapy (TX): implications of ECOG 5592 (Abstract No. 1912). Proc Am Soc Clin Oncol 2000;19.
13. Oshita F, Kurata T, Kasai T, et al. Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. Jpn J Cancer Res 1995;86:1198-1202.